BRCA1/BRCA2
Unique Identifier:
ML-N001
Name on Requisition:
BRCA1/BRCA2
Product Line:
NH
Panel Group:
Hereditary Cancer Panels
Panel Name:
BRCA1/BRCA2
Methodology
Molecular
NGS
Test Description and clinical significance
Genes
BRCA1/2
Disease:
breast, ovarian, pancreatic, and prostate cancers.
The BRCA1 and BRCA2 genes play critical roles in DNA repair through homologous recombination. Germline pathogenic variants in these genes are associated with a significantly increased risk of breast, ovarian, pancreatic, and prostate cancers. Detection of BRCA1/2 mutations provides diagnostic, prognostic, and therapeutic information, guiding cancer risk management, family counseling, and eligibility for PARP inhibitor therapy.
Specimen Requirements
Preparation:
PB, saliva
Collection:
Specimen should contain least 0.5 mL of peripheral blood (lower volumes may be accepted if situation demands), but we prefer larger specimens in case of a low content of nucleated cells. For saliva, it is recommended to request 1.5-2.0 ml of saliva to be collected from each patient.
Stability:
4 to 7 days refrigerated fpr PB and upto 1 year for slaiva at room temperature
Unacceptable Conditions:
Specimen submitted is in the incorrect fixative or anticoagulant. Specimen received after the stability date. Gross hemolysis. Frozen specimen. Insufficient specimen. Unlabeled. Left un-refrigerated for an extended period.
Storage & Transport
4 to 7 days refrigerated fpr PB and upto 1 year for slaiva at room temperature
CPT(s)
81162
New York Approved
Yes
TAT
14-21
Requisition Type
NH
Levels of Service
Full
DexS Code
Z03QG
Prefix
MI
*The CPT codes provided are for informational purposes only and are based on AMA guidelines The billing party is solely responsible for correct CPT coding.
